Comparative In Vitro Antimicrobial Activity of Tigecycline, a New Glycylcycline Compound, in Freshly Prepared Medium and Quality Control
- 1 July 2007
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 45 (7) , 2173-2179
- https://doi.org/10.1128/jcm.02351-06
Abstract
The in vitro spectra of activity of tigecycline and tetracycline were determined for 2,490 bacterial isolates representing 50 different species or phenotypic groups. All isolates were tested simultaneously by broth microdilution using freshly prepared Mueller-Hinton broth and by disk diffusion. Portions of these data were submitted to the Food and Drug Administration (FDA) in support of the sponsor's application for new drug approval. In a separate study, MIC and disk diffusion quality control ranges were determined. The tigecycline MICs at which 50%/90% of bacteria were inhibited were (in μg/ml) as follows: for Streptococcus spp., 0.06/0.12; for Moraxella catarrhalis , 0.06/0.12; for Staphylococcus spp., 0.12/0.25; for Enterococcus spp., 0.12/0.25; for Listeria monocytogenes , 0.12/0.12; for Neisseria meningitidis , 0.12/0.25; for Haemophilus spp., 0.25/0.5; for Enterobacteriaceae , 0.05/2.0; for non- Enterobacteriaceae , 0.5/8.0. Tigecycline was consistently more potent than tetracycline against all species studied. The data from this study confirm the FDA-approved MIC and disk diffusion breakpoints for tigecycline for Streptococcus spp. other than Streptococcus pneumoniae , enterococci, and Enterobacteriaceae . Provisional breakpoints for Haemophilus spp. and S. pneumoniae are proposed based on the data from this study. The following MIC and/or disk diffusion quality control ranges are proposed: Staphylococcus aureus ATCC 29213, 0.03 to 0.25 μg/ml; S. aureus ATCC 25923, 20 to 25 mm; Escherichia coli ATCC 25922, 0.03 to 0.25 μg/ml and 20 to 27 mm; Pseudomonas aeruginosa ATCC 27853, 9 to 13 mm, Enterococcus faecalis ATCC 29212, 0.03 to 0.12 μg/ml; S. pneumoniae ATCC 49619, 0.015 to 0.12 μg/ml and 23 to 29 mm; Haemophilus influenzae ATCC 49247, 0.06 to 0.5 μg/ml and 23 to 31 mm; and Neisseria gonorrhoeae ATCC 49226, 30 to 40 mm.Keywords
This publication has 20 references indexed in Scilit:
- In Vitro Activity of Tigecycline against Isolates from Patients Enrolled in Phase 3 Clinical Trials of Treatment for Complicated Skin and Skin‐Structure Infections and Complicated Intra‐Abdominal InfectionsClinical Infectious Diseases, 2005
- Effect of Medium Age and Supplementation with the Biocatalytic Oxygen-Reducing Reagent Oxyrase on In Vitro Activities of Tigecycline against Recent Clinical IsolatesAntimicrobial Agents and Chemotherapy, 2005
- Tigecycline MIC Testing by Broth Dilution Requires Use of Fresh Medium or Addition of the Biocatalytic Oxygen-Reducing Reagent Oxyrase To Standardize the Test MethodAntimicrobial Agents and Chemotherapy, 2005
- In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004)Diagnostic Microbiology and Infectious Disease, 2005
- In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002Diagnostic Microbiology and Infectious Disease, 2005
- Activity of Tigecycline (GAR-936) against Acinetobacter baumannii Strains, Including Those Resistant to ImipenemAntimicrobial Agents and Chemotherapy, 2004
- In Vitro Activities of Tigecycline against Erythromycin-Resistant Streptococcus pyogenes and Streptococcus agalactiae : Mechanisms of Macrolide and Tetracycline ResistanceAntimicrobial Agents and Chemotherapy, 2004
- In Vitro Activities of Tigecycline (GAR-936) against Multidrug-Resistant Staphylococcus aureus and Streptococcus pneumoniaeAntimicrobial Agents and Chemotherapy, 2004
- Activities of the Glycylcycline Tigecycline (GAR-936) against 1,924 Recent European Clinical Bacterial IsolatesAntimicrobial Agents and Chemotherapy, 2003
- In Vitro and In Vivo Activities of Tigecycline (GAR-936), Daptomycin, and Comparative Antimicrobial Agents against Glycopeptide-IntermediateStaphylococcus aureusand Other Resistant Gram-Positive PathogensAntimicrobial Agents and Chemotherapy, 2002